1053-74-3

Basic information

• Product Name: 2-Acetyl-10-[3-(4-methylpiperazino)propyl]-10H-phenothiazine
• Synonyms: 1-[10-[3-(4-Methylpiperazino)propyl]-10H-phenothiazin-2-yl]ethanone;2-Acetyl-10-[3-(4-methylpiperazino)propyl]-10H-phenothiazine
• CAS NO: 1053-74-3
• Molecular Formula: C22H27 N3 O S
• Molecular Weight: 381.58
• Mol File: 1053-74-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 554.8°Cat760mmHg
• Flash Point: 289.3°C
• Appearance: /
• Density: 1.0881 (rough estimate)
• Vapor Pressure: 2.39E-12mmHg at 25°C
• Refractive Index: 1.6740 (estimate)
• CAS DataBase Reference: 2-Acetyl-10-[3-(4-methylpiperazino)propyl]-10H-phenothiazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Acetyl-10-[3-(4-methylpiperazino)propyl]-10H-phenothiazine(1053-74-3)
• EPA Substance Registry System: 2-Acetyl-10-[3-(4-methylpiperazino)propyl]-10H-phenothiazine(1053-74-3)

Safety Data

• Hazardous Substances Data: 1053-74-3(Hazardous Substances Data)

Usage

Safety Profile

A poison by intravenous route. Moderately toxic by ingestion. A flammable liquid. When heated to decomposition it emits toxic vapors of soX,.

InChI:InChI=1/C22H27N3OS/c1-17(26)18-8-9-22-20(16-18)25(19-6-3-4-7-21(19)27-22)11-5-10-24-14-12-23(2)13-15-24/h3-4,6-9,16H,5,10-15H2,1-2H3

Upstream product

• 6631-94-3 2-acetylphenothiazine 
• 2031-23-4 3-(4-methyl-1-piperazinyl)propyl chloride dihydrochloride 
• 109-01-3 1-methyl-piperazine 
• 134318-13-1 3-(2-acetyl-10H-phenothiazin-10-yl)-propyl bromide 
• 104-16-5 3-(N-methylpiperazinyl)propyl chloride 

Downstream Products

• 102344-12-7 2-acetyl-10-[3-(4-methylpiperazino)propyl]phenothiazin bis-(hydrogen maleate) 

Relevant articles and documents

Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents

Chemotherapy is one of the most important methods in the treatment of cancer. However, development of drug resistance during chemotherapy is the leading cause of treatment failure and decreased survival in cancer patients. Multidrug resistance (MDR) is one of the extensively studied forms of drug resistance for more than 30 years. The members of ATP-binding cassette protein family are responsible for multidrug resistance with P-glycoprotein as most representative transporter. To overcome multidrug resistance, pharmacological modulation of the transporters by efflux pump inhibitors seem to be the first choice, but preclinical studies did not lead to clinical applications. Therefore, a systematical research for pharmacophor structures is a promising strategy to increase the efficacy of those drugs still influencing multidrug resistance. In this study a range of phenothiazine derivatives was synthesizied with systematical variation of three molecule domains. The biochemical determination of multidrug resistance reversal activity was achieved with the crystalviolet assay on LLC-PK1/MDR1 cells. The results will be discussed considering of hypotheses in the literature directed to new structure-acitivity relationships to overcome drug resistance in the future.